CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel's $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the Firm

Core Viewpoint - Cerevel Therapeutics is set to be acquired by AbbVie for $45.00 per share, valuing the company at approximately $8.7 billion, with the transaction expected to close in mid-2024 [1] Group 1: Acquisition Details - AbbVie will acquire all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash [1] - The total equity value of the transaction is approximately $8.7 billion [1] - The boards of directors of both companies have approved the transaction [1] Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating the acquisition, alleging that Cerevel's board was conflicted and engaged in an unfair process [2][5] - Current shareholders of Cerevel are encouraged to submit their information to understand their rights regarding the transaction [2][3]